RE: RE: RE: RE: RE: mbx My recent conversations with Vaughn confirm your assessment and my thoughts, exactly.
Aswell, we discussed the status of Novartis challenge and vaccine production. Very enlightening.
I came away knowing that our patent is extremely valuable to companies like Novartis who make vaccines. When our patent is incorporated into their manufacturing processes the end result is much larger yields in vaccine production using a fraction of the raw materials (eggs) needed. i am sure Novartis (and others) would love to utilize this technology (if they haven't already ... ??) without having to deal with patent infringement. The dollars in compensation to MBX WILL amount to big $$$$! PerhapsNovartis and others will decide to settlement outside the courts. I guess anything is possible. One thing is for sure, Vaughn is making it a priority to ensure we get the most value out of this technology.
I don't think Novartis has a "snowballs chance in hell" in succeeding with their opposition to our patent claims. It's interesting to note that we were granted a patent in the United States and one patent in Europe. As well, while the patent process was pending there was no one that opposed or raised issue with our claims, not anyone.
Anyway, the process has a mind of it's own and it will take time to resolve and come to a decision. We need to be patient and let it take it course. There's not much new on the European Patent Register but alot going on behind the scenes.
Anyway that's my rant for now ...
Buy, hold and accumulate.